276 related articles for article (PubMed ID: 17039392)
21. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
Deraco M; Casali P; Inglese MG; Baratti D; Pennacchioli E; Bertulli R; Kusamura S
J Surg Oncol; 2003 Jul; 83(3):147-53. PubMed ID: 12827682
[TBL] [Abstract][Full Text] [Related]
22. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
[TBL] [Abstract][Full Text] [Related]
23. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Yan TD; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2007 Aug; 14(8):2289-99. PubMed ID: 17541772
[TBL] [Abstract][Full Text] [Related]
24. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Feldman AL; Libutti SK; Pingpank JF; Bartlett DL; Beresnev TH; Mavroukakis SM; Steinberg SM; Liewehr DJ; Kleiner DE; Alexander HR
J Clin Oncol; 2003 Dec; 21(24):4560-7. PubMed ID: 14673042
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive management of diffuse malignant peritoneal mesothelioma.
Sugarbaker PH; Yan TD; Stuart OA; Yoo D
Eur J Surg Oncol; 2006 Aug; 32(6):686-91. PubMed ID: 16621431
[TBL] [Abstract][Full Text] [Related]
26. Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials.
Kluger MD; Taub RN; Hesdorffer M; Jin Z; Chabot JA
Eur J Surg Oncol; 2010 Oct; 36(10):997-1003. PubMed ID: 20674253
[TBL] [Abstract][Full Text] [Related]
27. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
Yan TD; Links M; Xu ZY; Kam PC; Glenn D; Morris DL
Br J Surg; 2006 Oct; 93(10):1270-6. PubMed ID: 16838392
[TBL] [Abstract][Full Text] [Related]
29. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
Yan TD; Boyer M; Tin MM; Wong D; Kennedy C; McLean J; Bannon PG; McCaughan BC
J Thorac Cardiovasc Surg; 2009 Sep; 138(3):619-24. PubMed ID: 19698846
[TBL] [Abstract][Full Text] [Related]
30. Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma.
Saxena A; Chua TC
Lung Cancer; 2009 Nov; 66(2):269-70. PubMed ID: 19733416
[No Abstract] [Full Text] [Related]
31. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
32. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
33. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
da Silva RG; Sugarbaker PH
J Am Coll Surg; 2006 Dec; 203(6):878-86. PubMed ID: 17116556
[TBL] [Abstract][Full Text] [Related]
34. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.
Begossi G; Gonzalez-Moreno S; Ortega-Perez G; Fon LJ; Sugarbaker PH
Eur J Surg Oncol; 2002 Feb; 28(1):80-7. PubMed ID: 11869020
[TBL] [Abstract][Full Text] [Related]
35. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
[TBL] [Abstract][Full Text] [Related]
36. The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome.
Brouquet A; Goéré D; Lefèvre JH; Bonnet S; Dumont F; Raynard B; Elias D
Ann Surg Oncol; 2009 Oct; 16(10):2744-51. PubMed ID: 19626375
[TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
[TBL] [Abstract][Full Text] [Related]
38. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Sugarbaker PH; Chang D
Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
[TBL] [Abstract][Full Text] [Related]
39. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution.
Nonaka D; Kusamura S; Baratti D; Casali P; Cabras AD; Younan R; Rosai J; Deraco M
Cancer; 2005 Nov; 104(10):2181-8. PubMed ID: 16206294
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Yang XJ; Li Y; al-shammaa Hassan AH; Yang GL; Liu SY; Lu YL; Zhang JW; Yonemura Y
Ann Surg Oncol; 2009 Feb; 16(2):345-51. PubMed ID: 19018599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
